1 unchanged sentence
Insider Trading Arrangements and Policies
−Removed: During the quarter ended March 31, 2025, no director or officer of the Company adopted or terminated a “ Rule 10b5-1 trading arrangement ” or “ non-Rule 10b5-1 trading arrangement, ” as each term is defined in Item 408(a) of Regulation S-K.
+Added: During the three months ended June 30, 2025, no director or officer of the Company adopted or terminated a “ Rule 10b5-1 trading arrangement ” or “ non-Rule 10b5-1 trading arrangement, ” as each term is defined in Item 408(a) of Regulation S-K.
Availability of Information
Solventum’s website address is www.solventum.com.
−Removed: Investors and others should note that the Company announces material information to its investors using SEC filings, press releases, its investor relations website, public conference calls and webcasts.
−Removed: The Company uses these channels to communicate with investors, customers and the public about the Company, its products and other issues.
+Added: Investors and others should note that the Company announces material information to its investors using SEC filings, press releases, its investor relations website, public conference calls, webcasts and certain social media channels, including the following LinkedIn accounts:
+Added: https://www.linkedin.com/in/bryanchanson/, and https://www.linkedin.com/in/wayde-mcmillan-9b233b33/.
+Added: The Company uses these channels to communicate with investors, customers and the public about the Company, its products and other issues and for complying with its disclosure obligations under Regulation FD.
The information on, or that may be accessed through, Solventum’s website is not incorporated by reference into this Quarterly Report on Form 10-Q and should not be considered a part of this Quarterly Report on Form 10-Q.
(2.1) Transaction Agreement by and between Solventum Corporation and Thermo Fisher Scientific Inc.
−Removed: (incorporated by reference to Exhibit 2.1 from Solventum Corporation's Form 8-K, filed February 27, 2025)
−Removed: (3.1) Amended and Restated Certificate of Incorporation of Solventum Corporation (incorporated by reference to Exhibit 3.1 from Solventum Corporation's Form 8-K, filed April 4, 2024)
−Removed: (3.2) Amended and Restated Bylaws of Solventum Corporation (incorporated by reference to Exhi bit 3.1 from Solventum Corporation's Form 8-K, filed September 26, 2024)
+Added: (incorporated by reference to Exhibit 2.1 from Solventum 's Form 8-K, filed February 27, 2025)
+Added: (2.2) A mended a nd Restated Transact ion Agreement b y and between Solventum Corporation and Thermo Fisher Scientific Inc.
+Added: (incorporate d by reference to Exhibit 2.1 fr om Solventum 's Fo rm 8-K filed June 25 , 2025)
+Added: (3.1) Amended and Restated Certificate of Incorporation of Solventum Corporation (incorporated by reference to Exhibit 3.1 from Solventum 's Form 8-K, filed April 4, 2024)
+Added: (3.2) Amended and Restated Bylaws of Solventum Corporation (incorporated by reference to Exhibit 3.1 from Solventum 's Form 8-K, filed September 26, 2024)
(4.1) Indenture, dated as of February 27, 2024, between Solventum Corporation and U.S.
3 unchanged sentences
2 to the Company's Registration Statement on Form 10, filed March 11, 2024.
−Removed: (10.15) Solventum 2024 Long-Term Incentive Plan Performance Share Unit Awards Agreement (incorporated herewith )
Filed herewith, in addition to items, if any, specifically identified above:
16 unchanged sentences
SOLVENTUM CORPORATION
+Added: August 7, 2025
By /s/ Wayde McMillan
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.